Mark S Cohen - Net Worth and Insider Trading
Mark S Cohen Net Worth
The estimated net worth of Mark S Cohen is at least $118,227 dollars as of 2024-11-14. Mark S Cohen is the Director of Akari Therapeutics PLC and owns about 52,780 shares of Akari Therapeutics PLC (AKTX) stock worth over $118,227. Details can be seen in Mark S Cohen's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mark S Cohen has not made any transactions after 2015-09-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Mark S Cohen
Mark S Cohen Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark S Cohen owns 1 companies in total, including Akari Therapeutics PLC (AKTX) .
Click here to see the complete history of Mark S Cohen’s form 4 insider trades.
Insider Ownership Summary of Mark S Cohen
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| AKTX | Akari Therapeutics PLC | 2015-09-18 | director |
Mark S Cohen Latest Holdings Summary
Mark S Cohen currently owns a total of 1 stock. Mark S Cohen owns 52,780 shares of Akari Therapeutics PLC (AKTX) as of September 18, 2015, with a value of $118,227.
Latest Holdings of Mark S Cohen
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| AKTX | Akari Therapeutics PLC | 2015-09-18 | 52,780 | 2.24 | 118,227 |
Holding Weightings of Mark S Cohen
Mark S Cohen Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark S Cohen has made a total of 0 transactions in Akari Therapeutics PLC (AKTX) over the past 5 years. The most-recent trade in Akari Therapeutics PLC is the acquisition of 52,780 shares on September 18, 2015, which cost Mark S Cohen around $200,564.
Insider Trading History of Mark S Cohen
- 1
Mark S Cohen Trading Performance
GuruFocus tracks the stock performance after each of Mark S Cohen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark S Cohen is -53.57%. GuruFocus also compares Mark S Cohen's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark S Cohen within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark S Cohen's insider trading performs compared to the benchmark.
Performance of Mark S Cohen
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -48.49 | | | | | |
| Relative Return to S&P 500(%) | -52.32 | | | | | |
Mark S Cohen Ownership Network
Ownership Network List of Mark S Cohen
Ownership Network Relation of Mark S Cohen
Mark S Cohen Owned Company Details
What does Akari Therapeutics PLC do?
Who are the key executives at Akari Therapeutics PLC?
Mark S Cohen is the director of Akari Therapeutics PLC. Other key executives at Akari Therapeutics PLC include General Counsel and Secretary Robert M Shaw , director & 10 percent owner James Hill , and director & 10 percent owner Stuart Ungar .
Akari Therapeutics PLC (AKTX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Akari Therapeutics PLC (AKTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akari Therapeutics PLC (AKTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Akari Therapeutics PLC (AKTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Akari Therapeutics PLC Insider Transactions
Mark S Cohen Mailing Address
Above is the net worth, insider trading, and ownership report for Mark S Cohen. You might contact Mark S Cohen via mailing address: C/o Celsus Therapeutics Plc, 24 West 40th Street, New York Ny 10018.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
